HC Wainwright Reaffirms “Buy” Rating for Valneva (NASDAQ:VALN)

HC Wainwright reissued their buy rating on shares of Valneva (NASDAQ:VALN) in a report published on Tuesday,Benzinga reports. HC Wainwright currently has a $17.00 price target on the stock.

Separately, Guggenheim reduced their price target on shares of Valneva from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, March 24th.

Valneva Stock Performance

Shares of VALN opened at $7.05 on Tuesday. The company has a market cap of $572.89 million, a price-to-earnings ratio of -54.23 and a beta of 1.85. The business’s fifty day simple moving average is $6.99 and its two-hundred day simple moving average is $5.64. Valneva has a 12 month low of $3.62 and a 12 month high of $9.50. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The business had revenue of $56.48 million for the quarter, compared to analysts’ expectations of $55.64 million. Research analysts anticipate that Valneva will post 0.13 earnings per share for the current fiscal year.

Institutional Trading of Valneva

Several large investors have recently modified their holdings of the company. GAMMA Investing LLC bought a new position in Valneva in the first quarter valued at about $94,000. ABC Arbitrage SA purchased a new stake in shares of Valneva during the 4th quarter valued at about $84,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock worth $1,079,000 after purchasing an additional 30,859 shares during the period. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.